MAXOLON

This brand name is authorized in Australia, Ireland, New Zealand, South Africa, UK.

Active ingredients

The drug MAXOLON contains one active pharmaceutical ingredient (API):

1	Metoclopramide UNII W1792A2RVD - METOCLOPRAMIDE HYDROCHLORIDE
	The action of metoclopramide is closely associated with parasympathetic nervous control of the upper gastro-intestinal tract where it has the effect of encouraging normal peristaltic action. This provides for a fundamental approach to the control of those conditions where disturbed gastrointestinal motility is a common underlying factor.
	Read more about Metoclopramide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MAXOLON Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
MAXOLON Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A03FA01	Metoclopramide	A Alimentary tract and metabolism → A03 Drugs for functional gastrointestinal disorders → A03F Propulsives → A03FA Propulsives
Discover more medicines within A03FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10762K, 1206L, 1207M, 12507G, 3476Y, 5151D, 5153F
GB	Medicines & Healthcare Products Regulatory Agency	15706
IE	Health Products Regulatory Authority	32374, 32921, 70246
NZ	Medicines and Medical Devices Safety Authority	668
ZA	Health Products Regulatory Authority	C/5.7.2/1014, C/5.7.2/918, C/5.7.2/920, H/5.7.2/200, H/5.7.2/201